Analysts predict that Theravance Biopharma Inc (NASDAQ:TBPH) will report ($1.31) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Theravance Biopharma’s earnings. The lowest EPS estimate is ($1.55) and the highest is ($0.97). Theravance Biopharma reported earnings of ($1.27) per share in the same quarter last year, which suggests a negative year over year growth rate of 3.1%. The firm is expected to issue its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Theravance Biopharma will report full-year earnings of ($4.55) per share for the current year, with EPS estimates ranging from ($5.04) to ($3.90). For the next fiscal year, analysts expect that the firm will report earnings of ($4.18) per share, with EPS estimates ranging from ($5.10) to ($3.34). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Theravance Biopharma.
Several research analysts have commented on TBPH shares. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a report on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. Leerink Swann increased their target price on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. ValuEngine cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, BidaskClub raised Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Theravance Biopharma presently has a consensus rating of “Hold” and an average target price of $42.00.
Theravance Biopharma (NASDAQ:TBPH) opened at $26.90 on Tuesday. The company has a market capitalization of $1,510.16, a price-to-earnings ratio of -4.94 and a beta of 1.78. Theravance Biopharma has a fifty-two week low of $22.90 and a fifty-two week high of $43.44. The company has a current ratio of 6.05, a quick ratio of 5.79 and a debt-to-equity ratio of 1.94.
Institutional investors have recently bought and sold shares of the company. Moneta Group Investment Advisors LLC acquired a new stake in shares of Theravance Biopharma in the 3rd quarter worth $299,000. SG Americas Securities LLC boosted its position in shares of Theravance Biopharma by 52.8% in the 3rd quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 3,130 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Theravance Biopharma in the 4th quarter worth $313,000. Parametric Portfolio Associates LLC boosted its position in shares of Theravance Biopharma by 1.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 217 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Theravance Biopharma in the 4th quarter worth $416,000. 86.62% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “-$1.31 EPS Expected for Theravance Biopharma Inc (TBPH) This Quarter” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/1-31-eps-expected-for-theravance-biopharma-inc-tbph-this-quarter.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.